Pfizer Aktie
| 24,65USD | 0,35USD | 1,42% |
WKN: 852009 / ISIN: US7170811035
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 78 500 | 79 000 | 83 000 | 88 000 | 81 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,53 | 1,03 | 1,21 | 0,66 | 0,79 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 35 067 | 59 693 | 51 259 | 43 333 | 50 358 |
| Summe Anlagevermögen | 119 162 | 121 783 | 145 946 | 183 168 | 163 038 |
| Summe Aktiva | 154 229 | 181 476 | 197 205 | 226 501 | 213 396 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 90 756 | 104 013 | 101 288 | 137 213 | 124 899 |
| Summe Eigenkapital | 63 473 | 77 463 | 95 917 | 89 288 | 88 497 |
| Summe Passiva | 154 229 | 181 476 | 197 205 | 226 501 | 213 396 |
Adresse
| 66 Hudson Boulevard East, 10001-2192 New York | |
| Telefon | +1 (212) 733-2323 |
| Internet | http://www.pfizer.com |
Management
|
Aamir Malik
Chief Commercial Officer-US & Executive VP |
|
Albert Bourla
Chairman & Chief Executive Officer |
|
Alexandre de Germay
Chief International Commercial Officer & EVP |
|
Andrew Baum
Executive VP, Chief Strategy & Innovation Officer |
|
Annaliesa Anderson
SVP, Head-Vaccine Research & Development |
|
Barbara J. Dalton
Vice President-Worldwide Business Development |
|
Berta Rodriguez-Hervas
Chief Artificial Intelligence & Analytics Officer |
|
Bryan Supran
Senior Vice President & Deputy General Counsel |
|
Chris Boshoff
President-R&D & Chief Scientific Officer |
|
Cyrus Russi Taraporevala
Non-Executive Director |
|
Dan R. Littman
Independent Director |
|
David M. Denton
Chief Financial Officer & Executive Vice President |
|
Denis Patrick
Executive Director & Vice President-WRDM |
|
Douglas M. Lankler
Chief Legal Officer & Executive Vice President |
|
Gordon Loh
Senior Vice President-Corporate Audit |
|
James C. Smith
Independent Director |
|
James F List
Chief Internal Medicine Officer |
|
James Quincey
Independent Director |
|
Jeff Settleman
Co-Chief Scientific Officer-Oncology |
|
Jeffrey Legos
Chief Oncology Officer |
|
Jennifer B. Damico
Senior Vice President & Controller |
|
John DeYoung
Vice President-Worldwide Business Development |
|
Joseph J. Echevarria
Independent Director |
|
Lidia L. Fonseca
Executive VP, Chief Technology & Digital Officer |
|
Lindsay Havern
Chief of Staff & SVP-Executive Operations |
|
Luis Jodar
Chief Medical Officer-Vaccines & Senior VP |
|
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP |
|
Maria Rivas
Chief Medical Affairs Officer |
|
Matthew J. Leonard
Senior Vice President-Global Access & Value |
|
Michael Mcdermott
EVP, Chief Global Supply & Quality Officer Officer |
|
Mortimer Joseph Buckley
Director |
|
Patrizia A. Cavazzoni
Chief Medical Officer & Executive Vice President |
|
Payal Sahni Becher
Chief People Experience Officer & Executive VP |
|
Rady A. Johnson
EVP, Chief Compliance, Quality & Risk Officer |
|
Ronald Edward Blaylock
Independent Director |
|
Sally Susman
Chief Corporate Affairs Officer & Executive VP |
|
Scott Gottlieb
Independent Director |
|
Shantanu Narayen
Lead Independent Director |
|
Susan D. Desmond-Hellmann
Independent Director |
|
Susan J. Hockfield
Independent Director |
|
Susan Rienow
Global Chief Marketing Officer |
|
Suzanne Nora Johnson
Independent Director |
|
William C. Sessa
SVP & Chief Scientific Officer-Internal Medicine |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.